The latest projects newly into human trials include BNT3212.

But results come from a curated dataset, with no in-trial comparator.

Global data are in the same ballpark as Chinese results presented earlier this year.

A common mutation comes into play for PRMT5 inhibition.

Tolerability could decide first-line therapy in EGFRm disease.

Investors now have more reasons to doubt Harmoni's ability to back US approval.